| 摘要 |
<p>Disclosed is the use of 1-hydroxy-2-(imidazol-1-yl)-ethane- 1,1-diphosphonic acid (zoledronic acid), or pharmaceutically acceptable salts or hydrates thereof in the preparation of a medicament for the treatment of conditions of abnormally increased bone turnover in which the 1-hydroxy-2-(imidazol-1-yl)- ethane-1,1-diphosphonic acid, or a pharmaceutically acceptable salt, or any hydrate thereof is administered intermittently, and in which the period between administrations is at least six months.</p> |
